Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Leonid Timashev

Biohaven Surges After FDA Cancels Key Meeting. But Is It Good News?

Biohaven stock surged Friday after the FDA canceled an upcoming meeting to discuss the benefits and risks of its drug, troriluzole.

Investors Business Daily

Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work?

Insmed stock is soaring as it approaches the potential approval of its second drug. CEO Will Lewis calls it a "skeleton key."

Investors Business Daily

Why Alkermes Tumbled On Its Positive Narcolepsy Study

Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug

CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug, DefenCath.

Investors Business Daily

This Little-Known Stock Could Be One of the Best Recession-Proof Investments Now

RBC flags this biopharma stock as recession-ready, with stellar upside potential hiding in plain sight.

Barchart

Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It

Bristol Myers Squibb stock skidded Tuesday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study.

Investors Business Daily

Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week

Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity

Biohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study.

Investors Business Daily

Biohaven Just Hurdled An FDA Setback — And Its Moving Lines

Biohaven stock hurdled its 50-day and 200-day lines Tuesday after the FDA granted its SCA treatment a speedier review time.

Investors Business Daily

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti.

Investors Business Daily

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.